Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Advances in Therapy

• Publication date

  2011-02-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12325-010-0101-yPMID 21318605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 176 A Randomized Controlled Trial of Rsv Prophylaxis with Motavizumab Vs Palivizumab in Young Children with Hemodynamically Significant Congenital Heart Disease

  2010cited by this paper
• Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

  2010cited by this paper
• Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

  2010cited by this paper
• Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.

  2008cited by this paper
• Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease

  2008cited by this paper
• Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

  2008cited by this paper
• Palivizumab Use in Subjects with Congenital Heart Disease

  2008cited by this paper
• Faculty Opinions recommendation of Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

  2007cited by this paper
• Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

  2007cited by this paper
• Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

  2007cited by this paper
• Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)*

  2006cited by this paper
• Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

  2005cited by this paper
• History of U.S. military contributions to the study of respiratory infections.

  2005cited by this paper
• Respiratory syncytial virus: The virus, the disease and the immune response

  2004cited by this paper
• Palivizumab Use in Very Premature Infants in the Neonatal Intensive Care Unit

  2004cited by this paper
• Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

  2004cited by this paper
• Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

  2003cited by this paper
• [Humanized respiratory syncytial virus monoclonal antibody].

  2002cited by this paper
• Respiratory syncytial virus infection in Navajo and White Mountain Apache children.

  2002cited by this paper
• Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease

  1999cited by this paper
• Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.

  1999cited by this paper
• A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

  1999cited by this paper
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

  1998cited by this paper
• Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

  1998cited by this paper
• Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.

  1998cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.

  1998cited by this paper
• Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

  1998cited by this paper
• Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease

  1998cited by this paper
• Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.

  1998cited by this paper
• Finally! the Brambell receptor (FcRB)

  1997cited by this paper
• Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections

  1997cited by this paper
• Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis

  1997cited by this paper
• Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

  1997cited by this paper
• Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

  1997cited by this paper
• The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

  1996cited by this paper
• Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.

  1996cited by this paper
• Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections

  1995cited by this paper
• Evaluation of the Protective Efficacy of Reshaped Human Monoclonal Antibody RSHZ19 against Respiratory Syncytial Virus in Cotton Rats

  1995cited by this paper
• Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.

  1995cited by this paper
• Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin.

  1994cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children

  1994cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

  1993cited by this paper
• Respiratory syncytial virus

  1993cited by this paper
• Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

  1993cited by this paper
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

  1993cited by this paper
• Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay.

  1992cited by this paper
• Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

  1991cited by this paper
• Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo

  1991cited by this paper
• Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

  1989cited by this paper
• Relation of Serum Antibody to Glycoproteins of Respiratory Syncytial Virus with Immunity to Infection in Children

  1987cited by this paper
• Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

  1987cited by this paper
• Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

  1985cited by this paper
• Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model.

  1985cited by this paper
• Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

  1979cited by this paper
• Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus.

  1976cited by this paper

• Effect of Breastfeeding on the Course of Respiratory Syncytial Virus Infection in Infants: A Single-Center Retrospective Study

  2025cites this paper
• Passive Immunization Strategies to Prevent Severe Respiratory Syncytial Virus Infection Among Newborns and Young Infants.

  2024cites this paper
• Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences

  2023cites this paper
• Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.

  2023cites this paper
• Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011–2021, Germany

  2022cites this paper
• Recommendations for respiratory syncytial virus surveillance at the national level

  2021cites this paper
• RSV neutralization assays - Use in immune response assessment.

  2021cites this paper
• Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

  2020cites this paper
• Current practices for respiratory syncytial virus surveillance across the EU/EEA Member States, 2017

  2019cites this paper
• Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016

  2018cites this paper
• Toward a virosomal respiratory syncytial virus vaccine with a built-in lipophilic adjuvant : A vaccine candidate for the elderly and pregnant women

  2018cites this paper
• Patterns of antibody response during natural hRSV infection: insights for the development of new antibody-based therapies

  2018cites this paper
• MicroRNAs: Mediators and Therapeutic Targets to Airway Hyper Reactivity After Respiratory Syncytial Virus Infection

  2018cites this paper
• Viral Upper Respiratory Tract Infections

  2017cites this paper
• A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard

  2017cites this paper
• A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.

  2017cites this paper
• Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease

  2016cites this paper
• Advances in RSV vaccine research and development - A global agenda.

  2016cites this paper
• Microbial Cryptotopes are Prominent Targets of B-cell Immunity

  2016cites this paper
• Protection of neonates and infants by maternal immunization

  2016cites this paper
• Respiratory tract infections in children with congenital heart disease

  2016cites this paper
• Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

  2014cites this paper
• [I Guidelines of heart failure and heart transplantation in the fetus, in children and adults with congenital cardiopathy, The Brazilian Society of Cardiology].

  2014cites this paper
• An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization

  2014cites this paper
• Infections néonatales virales

  2013cites this paper
• A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles

  2013cites this paper
• The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

  2013cites this paper
• A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

  2013cites this paper
• Antiviral Drug Discovery

  2013cites this paper
• Infecciones neonatales de origen viral

  2013cites this paper
• Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model.

  2013cites this paper
• Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy

  2012cites this paper
• Modelagem Molecular da Interação entre a Proteína de Fusão do Vírus Sincicial Respiratório Humano e Inibidores da Ação Viral

  2012cites this paper
• Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy

  2012cites this paper
• Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice

  2012cites this paper
• The Prophylaxis and Treatment with Antiviral Agents of Respiratory Syncytial Virus Infections

  2012cites this paper
• Respiratory viruses in neonates hospitalized with acute lower respiratory tract infections

  2012cites this paper
• Antibodies for prevention and treatment of respiratory syncytial virus infections in children.

  2012cites this paper
• Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs

  2011cites this paper
• Respiratory syncytial virus prevention in children with congenital heart disease: who and how?

  2011cites this paper